Skip to content

Efficacy of Multi-modal Brief Intervention for Tobacco Use Disorders in Depression.

Efficacy of a culturally tailored Multimodal Brief Intervention for Tobacco Use Disorder in Depression (MBIT-D): An Open Parallel arm Randomized Control Trial. - MBIT-D

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086226
Enrollment
148
Registered
2025-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F32- Major depressive disorder, singleepisode Health Condition 2: F17- Nicotine dependence

Interventions

Intervention1: Multi-modal Brief Intervention for Tobacco Use Disorders in Depression (MBIT-D), along with the standard treatment for depression.: MBIT-D will include Motivational Interviewing, cravin

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients clinically diagnosed with depressive disorder along with comorbid disorders of nicotine use, according to International Classification of Diseases, 11th Edition (ICD-11) (25). 2. Patients who are newly diagnosed with the above condition and/or drug na ve for at least 2 weeks. 3. Patients aged 18-65 years of either sex. 4. Patients who are current tobacco users (using once in the last 1 week). 5. Patients/ Legally Authorized Representative (LAR) giving voluntary written consent for participation.

Exclusion criteria

Exclusion criteria: 1. Presence of comorbid other substance use disorder in dependence pattern. 2. Critically ill patients, patients in acute emergency, and patients whose clinical condition is judged to hamper effective study participation.

Design outcomes

Primary

MeasureTime frame
Cessation from tobacco use at the end of 3 weeks and 6 weeks.Timepoint: Cessation from tobacco use at the end of 3 weeks and 6 weeks.

Secondary

MeasureTime frame
1. Change in tobacco use at the end of 3 weeks and 6 weeks. 2. Change in HDRS score at 3 weeks and 6 weeks. 3. Change in WHO-QoL-Bref score at 3 weeks and 6 weeks.Timepoint: 3 weeks and 6 weeks

Countries

India

Contacts

Public ContactSantanu Nath

All India Institute of Medical Sciences-Deoghar

doc.santanunath@gmail.com9337434349

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026